Topiramate is an anticonvulsant drug used to treat epilepsy in both children and adults, in many cases it can also be 
used as an antidepressant, most of the time for depressive realism. It is also Food and Drug Administration (FDA) approved for, and now most frequently prescribed for, the prevention of migraines (source: wikipedia.org).
In psychiatric disorders, Topiramate lacks efficacy in the treatment of acute mania. One of Annals of General Psychiatry Journals reviewed pharmacokinetic and pharmacodynamic profile of topiramate, its biological putative role in treating psychiatric disorders and its relevance in clinical practice. A comprehensive search from a range of electronic databases was conducted for the introduction of topiramate, according to the article.
Danilo Arnone from Department of Psychiatry, Springfield University Hospital, St George’s Medical School, London, UK concluded that increasing evidence, based on controlled studies, supports the use of topiramate in binge eating disorders, bulimia nervosa, alcohol dependence and possibly in bipolar disorders in depressive phase. Instead of pharmacokinetic and pharmacodynamic profile of topiramate, particular interest is focused on topiramate related weight loss and its clinical implications.
Complete information about Psychiatry Reviewed Journal : Topiramate for The Treatment of Psychiatric Disorder by downloading the full original article, here (source: annals-general-psychiatry.com). See also similar content in Psychiatri Journal within this site.
